The objective of this study was to determine whether quantitative volumetric changes as seen on contrast-enhanced magnetic resonance (MR) imaging can help assess early tumor response and predict survival

in patients with metastatic uveal melanoma after one session of TACE. This was a single-institution retrospective study. The study was compliant with the Health Insurance Portability and Accountability Act and was approved by the Institutional Review Board. Informed consent was waived. Entinostat order A review of the database of prospectively enrolled patients with uveal melanoma who underwent TACE at our institution from 2004 to 2014 was performed. A total of 21 patients were identified. Inclusion criteria were given as follows: 1) Ferroptosis inhibitor review diagnosis of liver metastasis confirmed by means of biopsy; 2) absence of previous systemic chemotherapy and/or liver directed therapies that might influence tumor response; 3) patients who underwent dynamic contrast-enhanced MR imaging before and approximately 3 to 4 weeks after TACE; 4) an

Eastern Cooperative Oncology Group performance status of up to 2; 5) additional criteria included Child-Pugh class; unifocal or multifocal hepatic malignancy; absent or limited extrahepatic malignancy; absent or trace ascites; albumin level of more than 2.5 g/dl; alanine aminotransferase and aspartate aminotransferase levels of less than five times the upper normal limit; total serum bilirubin level of less than 3.0 mg/dl; serum creatinine level of less than 2.0 mg/dl; platelet count of at least 50,000/mm3; international

normalized ratio of up to 1.5; at least partial patency of the portal venous system. Six patients were excluded for the following reasons: previous systemic and/or locoregional therapies this website (n = 1) and absence of follow-up MR imaging after TACE (n = 5). On the basis of these criteria, the final study population included 15 patients. Baseline characteristics are summarized in Table 1. All patients considered for TACE were discussed at our multidisciplinary liver tumor board. All TACE procedures were performed by one experienced interventional radiologist with 16 years of experience by using a consistent approach as reported previously [18]. Briefly, an 18-gauge single-wall needle was used with the Seldinger technique to access the right common femoral artery. A 5-F vascular sheath was placed over a 0.035-inch Bentson guidewire (Cook, Bloomington, IN). With fluoroscopic guidance, a 5-F Simmons-1 catheter (Cordis, Miami Lakes, FL) was advanced over the wire and reformed into the aortic arch and used to select the celiac axis. Then, a Renegade HI-FLO microcatheter was advanced over a Fathom-16 wire (Boston Scientific, Natick, MA) into the desired hepatic artery branch, depending on the tumor location. Selective catheterization was performed to achieve lobar or sub-/segmental embolization based on the targeted lesions.